UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 10-Q

(Mark One)
[X] Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange
    Act of 1934

                 For the quarterly period ended March 31, 2011

[ ] Transition report pursuant Section 13 or 15(d) of the Securities Exchange
    Act of 1934

             For the transition period from _________ to _________.

                        Commission file number 333-171892


                                 CONEX MD, INC.
             (Exact name of registrant as specified in its Charter)

             Nevada                                              26-1574051
  (State or other jurisdiction                                (I.R.S. Employer
of incorporation or organization)                            Identification No.)

            33 Herzel St.
          Ra'anana, Israel                                         43353
(Address of principal executive offices)                         (Zip Code)

                                (972) 57-946-1249
              (Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [ ] No [X]

Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss. 232.405
of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes [ ] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of "large accelerated filer," "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ ]                        Accelerated filer [ ]

Non-accelerated filer [ ]                          Smaller reporting company [X]
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [X] No [ ]

As of April 19, 2011, the Company had outstanding 8,475,500 shares of common
stock, par value $0.0001.
<PAGE>
                               TABLE OF CONTENTS

Part I - FINANCIAL INFORMATION................................................ 3

     Item 1.   Condensed Financial Statements................................. 3

     Item 2.   Management's Discussion and Analysis of Financial Condition
               and Results of Operations......................................10

     Item 3.   Quantitative and Qualitative Disclosures About Market Risk.....11

     Item 4.   Controls and Procedures........................................12

PART II - OTHER INFORMATION...................................................12

     Item 1.   Legal Proceedings..............................................12

     Item 1A.  Risk Factors...................................................12

     Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds....12

     Item 3.   Defaults Upon Senior Securities................................12

     Item 4.   Removed and Reserved...........................................12

     Item 5.   Other Information..............................................12

     Item 6.   Exhibits.......................................................12

SIGNATURES....................................................................13

                                       2
<PAGE>
                         PART I - FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

                                 CONEX MD, INC.
                          (A Development Stage Company)
                            Condensed Balance Sheets

<TABLE>
<CAPTION>
                                                                             March 31,        December 31,
                                                                               2011               2010
                                                                             --------           --------
                                                                            (Unaudited)        (Audited)
<S>                                                                          <C>                <C>
                                     ASSETS

CURRENT ASSETS:
  Cash                                                                       $ 49,095           $ 58,579
                                                                             --------           --------
      TOTAL CURRENT ASSETS                                                     49,095             58,579
                                                                             --------           --------

      TOTAL ASSETS                                                           $ 49,095           $ 58,579
                                                                             ========           ========

                      LIABILITIES AND STOCKHOLDERS' EQUITY

Accounts Payable                                                             $  2,767           $     --
                                                                             --------           --------
      TOTAL CURRENT LIABILITIES                                                 2,767                 --
                                                                             --------           --------

STOCKHOLDERS' EQUITY:
  Preferred stock, 50,000,000 shares authorized, par value $0.0001,
   no shares issued or outstanding                                                 --                 --
  Common stock, 100,000,000 shares authorized, par value $0.0001,
   8,475,500 shares issued and outstanding                                        848                848
  Additional paid in capital                                                   69,162             69,162
  Deficit accumulated during the development stage                            (23,682)           (11,431)
                                                                             --------           --------
      TOTAL STOCKHOLDERS' EQUITY                                               46,328             58,579
                                                                             --------           --------

      TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                             $ 49,095           $ 58,579
                                                                             ========           ========
</TABLE>


          See accompanying notes to the condensed financial statements.

                                       3
<PAGE>
                                 CONEX MD, INC.
                          (A Development Stage Company)
                       Condensed Statements of Operations
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                     December 13, 2007
                                                                    Three Months Ended                (Inception) to
                                                                         March 31,                       March 31,
                                                                 2011                 2010                 2011
                                                              ----------           ----------           ----------
<S>                                                           <C>                 <C>                  <C>
Revenue                                                       $       --           $       --           $       --

General and Administrative expenses                               12,251                  114               21,746
                                                              ----------           ----------           ----------
Operating loss                                                   (12,251)                (114)             (21,746)
                                                              ----------           ----------           ----------
Foreign currency loss                                                 --                   --               (1,936)
                                                              ----------           ----------           ----------
Loss before income taxes                                         (12,251)                (114)             (23,682)
Provision for Income Taxes                                            --                   --                   --
                                                              ----------           ----------           ----------

Net loss                                                      $  (12,251)          $     (114)          $  (23,682)
                                                              ==========           ==========           ==========

Basic and Diluted Loss Per Common Share                                a                    a                    a
                                                              ==========           ==========           ==========

Weighted Average Number of Common Shares Outstanding           8,475,500            5,000,000            5,401,837
                                                              ==========           ==========           ==========
</TABLE>

----------
a = less than $.01 per share


          See accompanying notes to the condensed financial statements.

                                       4
<PAGE>
                                 CONEX MD, INC.
                          (A Development Stage Company)
                   Condensed Statement of Stockholders' Equity
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                            Deficit
                                                                                          Accumulated
                                                     Common Stock           Additional    During the        Total
                                                ---------------------        Paid in      Development    Stockholders'
                                                Shares         Amount        Capital         Stage          Equity
                                                ------         ------        -------         -----          ------
<S>                                             <C>            <C>           <C>             <C>            <C>
BALANCES - DECEMBER 13, 2007 (INCEPTION)              --     $      --      $      --      $      --      $      --

Common stock issued  to directors for cash
 on December 13, 2007 ($0.0001)                5,000,000           500             --             --            500
                                               ---------     ---------      ---------      ---------      ---------
BALANCE DECEMBER 31, 2008                      5,000,000           500             --             --            500

Net loss for the year                                 --            --             --          1,815          1,815
                                               ---------     ---------      ---------      ---------      ---------
BALANCE DECEMBER 31, 2009                      5,000,000           500             --          1,815          2,315

Common stock issued for cash received
 in 2009 ($0.02)                                 215,000            22          4,278             --          4,300
Common stock issued for cash ($0.02)           3,260,500           326         64,884             --         65,210
Net loss for the year                                 --            --             --        (13,246)       (13,246)
                                               ---------     ---------      ---------      ---------      ---------
BALANCE DECEMBER 31, 2010                      8,475,500           848         69,162        (11,431)        58,579

Net loss for the quarter                              --            --             --        (12,251)       (12,251)
                                               ---------     ---------      ---------      ---------      ---------

BALANCE MARCH 31, 2011                         8,475,500     $     848      $  69,162      $ (23,682)     $  46,328
                                               =========     =========      =========      =========      =========
</TABLE>


          See accompanying notes to the condensed financial statements.

                                       5
<PAGE>
                                 CONEX MD, INC.
                          (A Development Stage Company)
                        Condensed Statements of Cashflows
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                              December 13, 2007
                                                                  Three Months Ended            (Inception) to
                                                                       March 31,                   March 31,
                                                               2011               2010               2011
                                                             --------           --------           --------
<S>                                                          <C>                <C>                <C>
OPERATING ACTIVITIES:
  Net loss                                                   $(12,251)          $   (114)          $(23,682)
  Adjustments to reconcile net loss to cash used in
   in operating activities:
     Increase in accounts payable                               2,767                 --              2,767
                                                             --------           --------           --------
           NET CASH USED IN OPERATING ACTIVITIES               (9,484)              (114)           (20,915)
                                                             --------           --------           --------
FINANCING ACTIVITIES:
  Proceeds from common stock subscriptions                         --                 --             70,010
                                                             --------           --------           --------
           CASH PROVIDED BY FINANCING ACTIVITIES                   --                 --             70,010
                                                             --------           --------           --------
Net Increase (Decrease) in Cash                                (9,484)              (114)            49,095

Cash, Beginning of Period                                      58,579              6,615                 --
                                                             --------           --------           --------

Cash, End of Period                                          $ 49,095           $  6,501           $ 49,095
                                                             ========           ========           ========

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
  Cash paid during the period for:
    Interest                                                 $     --           $     --           $     --
                                                             ========           ========           ========
    Income taxes                                             $     --           $     --           $     --
                                                             ========           ========           ========
</TABLE>


          See accompanying notes to the condensed financial statements.

                                       6
<PAGE>
                                 CONEX MD, INC.
                   NOTES TO THE CONDENSED FINANCIAL STATEMENTS
                        THREE MONTHS ENDED MARCH 31, 2011


NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION

The Company was  incorporated  under the laws of the state of Nevada on December
13, 2007.  The Company has limited  operations  and is  considered a development
stage company and has not yet realized any revenues from its planned operations.

Conex MD is a provider of  specialized  healthcare  staffing to small and medium
sized businesses.  We intend to recruit healthcare  professionals on assignments
of varied duration and in permanent positions with clients in the United States.
Our services will include hires in administration, information technology, sales
and at the executive level.

As a development stage enterprise, the Company discloses the deficit accumulated
during the  development  stage and the  cumulative  statements of operations and
cash flows from inception to the current balance sheet date.

In the opinion of management,  the accompanying  unaudited  condensed  financial
statements of Conex MD, Inc. (the "Company")  contain all adjustments  necessary
to present fairly the Company's  financial position as of March 31, 2011 and its
results of  operations  for the three  months  ended March 31, 2011 and 2010 and
cash flows for the three months ended March 31, 2011 and 2010. The  accompanying
unaudited  interim  financial  statements  have been prepared in accordance with
instructions  to Form 10-Q and  therefore  do not  include all  information  and
footnotes  required by accounting  principles  generally  accepted in the United
States of America.  The results of  operations  for the three months ended March
31, 2011 are not  necessarily  indicative  of the results to be expected for the
full year.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

USE OF ESTIMATES

The  preparation  of financial  statements  in  conformity  with U.S.  generally
accepted  accounting  principles  requires  management  to  make  estimates  and
assumptions  that affect the amounts reported in the financial  statements.  The
Company bases its estimates on historical  experience,  management  expectations
for future  performance,  and other  assumptions  as  appropriate.  The  Company
re-evaluates  its estimates on an ongoing  basis;  actual  results may vary from
those estimates.

CASH AND CASH EQUIVALENTS

The Company  considers  all highly  liquid  investments  with  maturity of three
months or less when purchased to be cash equivalents.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The  carrying  value  of the  Company's  financial  instruments,  consisting  of
accounts payable  approximate their fair value due to the short-term maturity of
such  instruments.  Unless otherwise noted, it is management's  opinion that the
Company is not exposed to significant interest, currency or credit risks arising
from these financial statements.

INCOME TAXES

A deferred  tax asset or liability  is recorded  for all  temporary  differences
between  financial  and tax reporting  and net  operating  loss carry  forwards.
Deferred tax expense  (benefit)  results from the net change  during the year of
deferred tax assets and liabilities.

                                       7
<PAGE>
Deferred tax assets are reduced by a valuation allowance when, in the opinion of
management,  it is more likely than not that some portion or all of the deferred
tax  assets  will not be  realized.  Deferred  tax assets  and  liabilities  are
adjusted  for the  effects  of  changes  in tax  laws  and  rates on the date of
enactment.

The Company's  practice is to recognize interest accrued related to unrecognized
tax benefits in interest  expense and  penalties in  operating  expenses.  As of
March 31, 2011 and  December 31,  2010,  the Company had no accrued  interest or
penalties.

LOSS PER SHARE

The basic loss per share is calculated by dividing our net loss  attributable to
common  shareholders by the weighted  average number of common shares during the
period.  The  diluted  loss per share is  calculated  by  dividing  our net loss
attributable to common  shareholders by the diluted  weighted  average number of
shares  outstanding  during the year.  The diluted  weighted  average  number of
shares  outstanding  is the basic weighted  number of shares  adjusted as of the
first of the year for any potentially  dilutive debt or equity.  The Company has
not issued any potentially dilutive financial instruments.

RECENTLY ISSUED ACCOUNTING STANDARDS

In October  2009,  the FASB issued  guidance on  "Multiple  Deliverable  Revenue
Arrangements,"  updating ASC 605 "Revenue  Recognition."  This standard provides
application   guidance  on  whether   multiple   deliverables   exist,  how  the
deliverables  should be separated and how the consideration  should be allocated
to one or more units of  accounting.  This update  establishes  a selling  price
hierarchy for determining the selling price of a deliverable.  The selling price
used for each deliverable will be based on vendor-specific  objective  evidence,
if available,  third-party evidence if vendor-specific objective evidence is not
available,  or estimated selling price if neither vendor-specific or third-party
evidence is  available.  The  guidance is  effective  prospectively  for revenue
arrangements entered into or materially modified in fiscal years beginning on or
after June 15, 2010.  The  Company's  adoption of this  guidance did not have an
impact on its financial statements and disclosures.

In April 2010, the FASB issued ASU No. 2010-17,  Revenue  Recognition--Milestone
Method (Topic 605): Milestone Method of Revenue  Recognition.  This ASU codifies
the  consensus  reached in EITF  Issue No.  08-9,  "Milestone  Method of Revenue
Recognition." The amendments to the Codification  provide guidance on defining a
milestone  and  determining  when it may be  appropriate  to apply the milestone
method  of  revenue  recognition  for  research  or  development   transactions.
Consideration  that is contingent on  achievement of a milestone in its entirety
may be  recognized  as revenue in the period in which the  milestone is achieved
only if the  milestone  is  judged to meet  certain  criteria  to be  considered
substantive.  Milestones should be considered  substantive in their entirety and
may  not  be  bifurcated.  An  arrangement  may  contain  both  substantive  and
nonsubstantive  milestones,  and each milestone should be evaluated individually
to determine  if it is  substantive.  ASU 2010-17 is effective on a  prospective
basis for milestones  achieved in fiscal years, and interim periods within those
years,  beginning on or after June 15, 2010.  Early adoption is permitted.  If a
vendor elects early  adoption and the period of adoption is not the beginning of
the entity's fiscal year, the entity should apply 2010-17  retrospectively  from
the beginning of the year of adoption.  The Company's  adoption of this guidance
did not have an impact on its financial statements.

Management  does  not  believe  that  any  other  recently  issued,  but not yet
effective,  accounting  standards  if  currently  adopted  would have a material
effect on the accompanying consolidated financial statements.

NOTE 3. INCOME TAXES

The Company uses the liability method, where deferred tax assets and liabilities
are  determined  based on the  expected  future tax  consequences  of  temporary
differences between the carrying amounts of assets and liabilities for financial
and income tax reporting  purposes.  Since its inception through March 31, 2011,

                                       8
<PAGE>
the Company has incurred net losses and,  therefore,  has no tax liability.  The
net  deferred  tax asset  generated  by the loss  carry-forward  has been  fully
reserved.  The  cumulative  net operating loss  carry-forward  is  approximately
$23,682 and will expire 20 years from the date the loss was incurred.

The Company did not  identify any material  uncertain  tax  positions on returns
that have been filed or that will be filed.

The Company has filed income tax returns in the United States. All tax years are
closed by expiration of the statute of limitations.

NOTE 4. STOCKHOLDER'S EQUITY

AUTHORIZED

The  Company is  authorized  to issue  100,000,000  shares of $0.0001  par value
common stock and 50,000,000  shares of preferred stock,  par value $0.0001.  All
common stock shares have equal voting rights,  are  non-assessable  and have one
vote per share. Voting rights are not cumulative and, therefore,  the holders of
more than 50% of the common stock  could,  if they choose to do so, elect all of
the directors of the Company.

ISSUED AND OUTSTANDING

On December 13, 2007, the Company issued  2,500,000 common shares to each of its
Directors for cash consideration of $0.0001 per share.

Since  inception  (December 13, 2007) to October 31, 2010, the Company  accepted
subscriptions for 3,475,500 shares of common stock from 36 investors pursuant to
a series of private  placement  transactions  which closed on July 1, 2010.  The
private placements were not subject to any minimum  investment,  and were priced
at $0.02 per share, for aggregate gross proceeds of approximately $69,510.

During the year ended December 31, 2009, the Company received proceeds of $4,300
for the sale of common stock that was issued In July 2010.

NOTE 5. RELATED PARTY TRANSACTIONS

The  officers  and  directors  of the  Company are  involved  in other  business
activities  and  may,  in  the  future,   become   involved  in  other  business
opportunities.  If a  specific  business  opportunity  becomes  available,  such
persons  may face a conflict  in  selecting  between the Company and their other
business  interests.  The Company has not formulated a policy for the resolution
of such conflicts.

During the year ended  December  31,  2010,  the Company paid two members of its
board of directors professional fees totaling $9,280.

NOTE 6. GOING CONCERN

The  accompanying  financial  statements  have been  prepared  assuming that the
Company  will  continue as a going  concern.  The Company has net losses for the
period from  inception  (December 13, 2007) to March 31, 2011, of $23,682.  This
condition raises  substantial doubt about the Company's ability to continue as a
going concern. The Company's continuation as a going concern is dependent on its
ability  to meet its  obligations,  to  obtain  additional  financing  as may be
required and ultimately to attain profitability. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.

Management  is  planning  to  raise  additional  funds  through  debt or  equity
offerings.  There is no guarantee  that the Company will be  successful in these
efforts.

                                       9
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

This discussion and analysis should be read in conjunction with the accompanying
Condensed Financial Statements and related notes. Our discussion and analysis of
our financial condition and results of operations are based upon our condensed
financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States. The preparation of financial
statements in conformity with accounting principles generally accepted in the
United States of America requires us to make estimates and assumptions that
affect the reported amounts of assets and liabilities, disclosure of any
contingent liabilities at the financial statement date and reported amounts of
revenue and expenses during the reporting period. On an on-going basis we review
our estimates and assumptions. Our estimates are based on our historical
experience and other assumptions that we believe to be reasonable under the
circumstances. Actual results are likely to differ from those estimates under
different assumptions or conditions. Our critical accounting policies, the
policies we believe are most important to the presentation of our financial
statements and require the most difficult, subjective and complex judgments, are
outlined in Note 2. To the condensed financial statements above, and have not
changed significantly.

FORWARD-LOOKING STATEMENTS

Certain statements made in this report may constitute "forward-looking
statements on our current expectations and projections about future events".
These forward-looking statements involve known or unknown risks, uncertainties
and other factors that may cause the actual results, performance, or
achievements of the Company to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. In some cases you can identify forward-looking statements by
terminology such as "may," "should," "potential," "continue," "expects,"
"anticipates," "intends," "plans," "believes," "estimates," and similar
expressions. These statements are based on our current beliefs, expectations,
and assumptions and are subject to a number of risks and uncertainties. Although
we believe that the expectations reflected-in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity, performance
or achievements. These forward-looking statements are made as of the date of
this report, and we assume no obligation to update these forward-looking
statements whether as a result of new information, future events, or otherwise,
other than as required by law. In light of these assumptions, risks, and
uncertainties, the forward-looking events discussed in this report might not
occur and actual results and events may vary significantly from those discussed
in the forward-looking statements.

GENERAL

The following discussion and analysis should be read in conjunction with our
financial statements and related footnotes for the year ended December 31, 2010
included in our Form S-1/A filed with the Securities and Exchange Commission on
April 19, 2011. The discussion of results, causes and trends should not be
construed to imply any conclusion that such results or trends will necessarily
continue in the future.

OVERVIEW

Conex MD, Inc. was incorporated on December 13, 2007, under the laws of the
State of Nevada. We are a development stage company formed for the purpose of
providing specialized healthcare staffing to small and medium sized businesses.
We recruit healthcare professionals on assignments of varied duration and in
permanent positions with clients in the United States.

                                       10
<PAGE>
LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2011 we had $49,095 in current assets (consisting of solely
cash), current liabilities of $2,767 (consisting entirely of accounts payable)
and a working capital surplus of $46,328. As of March 31, 2011 we had total
assets of $49,095.

During the period from December 13, 2007 (inception) to March 31, 2011 we used
$20,915 of cash in operations and received net cash of $70,010 from financing
activities comprised entirely of sales of our equity securities less offering
costs.

During the three months ended March 31, 2011 and 2010 we used cash of $9,484 and
$114 in operations, respectively.

RESULTS OF OPERATIONS

COMPARISON OF THE THREE MONTHS ENDED MARCH 31, 2011 AND 2010

OPERATING EXPENSES

The Company's operating expenses increased by $12,137 from $114 for the three
months ended March 31, 2010 to $12,251 for the three months ended March 31,
2011. The Company's operating expenses for 2011 consisted of professional fees
related to the filing of a registration statement with the SEC of $9,115,
consulting fees related to the development of the business of $1,770, website
development costs of $600, a transfer agent set up fee of $500, and bank
services charges of $266.

GOING CONCERN

We have incurred net losses of $23,682 from our inception on December 13, 2007
to March 31, 2011 and have completed only the preliminary stages of our business
plan. We anticipate incurring additional losses before realizing any revenues
and will depend on additional financing in order to meet our continuing
obligations and ultimately, to attain profitability. Our ability to obtain
additional financing, whether through the issuance of additional equity or
through the assumption of debt, is uncertain. Accordingly, our independent
auditors' report on our financial statements for the year ended December 31,
2010 include an explanatory paragraph regarding concerns about our ability to
continue as a going concern, including additional information contained in the
notes to our financial statements describing the circumstances leading to this
disclosure. The financial statements do not include any adjustments that might
result from the uncertainty about our ability to continue our business.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

We do not expect the adoption of any recently issued accounting pronouncements
to have a significant impact on our net results of operations, financial
position, or cash flows.

OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

N/A

                                       11
<PAGE>
ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

The Company's Principal Executive Officer and Principal Financial Officer have
evaluated the effectiveness of the Company's disclosure controls and procedures
(as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March
31, 2011. Based upon such evaluation, the Principal Executive Officer and
Principal Financial Officer have concluded that, as of March 31, 2011, the
Company's disclosure controls and procedures were effective.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

No change in the Company's internal control over financial reporting occurred
during the quarter ended March 31, 2011, that materially affected, or is
reasonably likely to materially affect, the Company's internal control over
financial reporting.

                           PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company knows of no material, existing or pending legal proceedings against
it. There are no proceedings in which any of the Company's directors, officers
or affiliates, or any registered or beneficial stockholder, is an adverse party
or has a material interest adverse to the Company.

ITEM 1A. RISK FACTORS

This item is not applicable to smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. RESERVED

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit
Number                         Description
------                         -----------

31.1     Certification of CEO Pursuant to 18 U.S.C. ss. 1350, Section 302

31.2     Certification of CFO Pursuant to 18 U.S.C. ss. 1350, Section 302

32.1     Certification Pursuant to 18 U.S.C. ss.1350, Section 906

32.2     Certification Pursuant to 18 U.S.C. ss. 1350, Section 906

                                       12
<PAGE>
                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                        CONEX MD, INC.


Date: May 13, 2011                      By: /s/ Dr. Ely Steinberg
                                            ------------------------------------
                                            Dr. Ely Steinberg,
                                            President and Director
                                            (Principal Executive Officer)


                                        CONEX MD, INC.


Date: May 13, 2011                      By: /s/ Dr. Jacob Bar-Ilan
                                            ------------------------------------
                                            Dr. Jacob Bar-Ilan,
                                            Secretary, Treasurer and Director
                                            (Principal Accounting Officer and
                                            Principal Financial Officer)

                                       13